Aquarray's DMA technology enables miniaturisation of screening experiments, resulting in significant material and cost savings. Recognizing the potential, numerous equipment and biotechnology companies have partnered with Aquarray to solve specific analytical problems.
One important topic is increasing the efficiency of cell screening with standard dispensers as well as with normal and special cell media. Other topics relate to MALDI-MS analysis, such as high-throughput readout of high-density droplet microarrays based on MALDI-MS, to enable the next generation of on-chip drug discovery, or modified target surfaces to improve performance in MALDI-MS analysis. Relevant application notes can be found on the Aquarray website https://www.aquarray.com/....
To support Aquarray´s continued development and growth, Dr. Tim Friedrichson has been appointed CEO of the company. He previously worked in the start-up industry and as a translation manager at the Max Planck Institute of Molecular Cell Biology and Genetics.
The previous CEO, Dr. Angelika Weinländer, has left the company.
One important topic is increasing the efficiency of cell screening with standard dispensers as well as with normal and special cell media. Other topics relate to MALDI-MS analysis, such as high-throughput readout of high-density droplet microarrays based on MALDI-MS, to enable the next generation of on-chip drug discovery, or modified target surfaces to improve performance in MALDI-MS analysis. Relevant application notes can be found on the Aquarray website https://www.aquarray.com/....
To support Aquarray´s continued development and growth, Dr. Tim Friedrichson has been appointed CEO of the company. He previously worked in the start-up industry and as a translation manager at the Max Planck Institute of Molecular Cell Biology and Genetics.
The previous CEO, Dr. Angelika Weinländer, has left the company.
